NEW YORK (GenomeWeb News) — Insight Genetics said yesterday that it has received a new $1.5 million grant from the National Cancer Institute.

The Phase II Small Business Innovation Research grant from the National Cancer Institute will enable Nashville, Tenn.-based Insight to continue developing Insight ALK Resistance, a molecular diagnostic test to help clinicians monitor therapeutic resistance in non-small cell lung cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.